{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-069441","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.751063+00:00","generated_at":"2026-06-27T00:53:18.108319+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"MiNK Therapeutics finalizes employment agreements for CEO ($425k) and CSO (£260k)","bullets":["CEO Dr. Buell: $425,000 base salary, 50% bonus target, compensation retroactive to Jan 1, 2022.","CSO Dr. van Dijk: £260,000 base salary, £18,000 housing/travel budget, 35% bonus target.","Without cause termination: Buell receives 12 months salary, bonus, COBRA, and $15k outplacement.","Change-in-control: Buell gets 18 months salary plus 150% bonus, full vesting acceleration of equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-069441","json":"https://secwatch.observer/filing/0001193125-22-069441.json","markdown":"https://secwatch.observer/filing/0001193125-22-069441.md","text":"https://secwatch.observer/filing/0001193125-22-069441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312522069441/0001193125-22-069441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312522069441/d69538d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:53:18.108319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}